SCHEMBL336033

SCHEMBL336033

COCc1cc(C(C)NCCN)ccc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCE Q02156 3/20 0.37
MAPT P10636 3/20 0.37
MYLK Q15746 2/20 0.37
MEN1 O00255 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
PRKCG P05129 1/20 0.37
PRKCA P17252 1/20 0.37
APEX1 P27695 1/20 0.37
RECQL P46063 1/20 0.37
NFKB1 P19838 3/20 0.35
SLC22A3 O75751 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
ADRB3 P13945 3/20 0.34
ADRB2 P07550 5/20 0.34
RRM1 P23921 1/20 0.34
ADRB1 P08588 2/20 0.33
MTOR P42345 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244522 0.82 RRM1 (0.42) PRKCEALDH1A1SLC22A3ADRB3RRM1
SCHEMBL335431 0.80 NFKB1 (0.57) NFKB1SLC22A3BLMPMP22TSHR
SCHEMBL336000 0.80 PRKCI (0.51) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL334300 0.76 CACNA1B (0.52) ALDH1A1CYP1A2TSHRHIF1ALMNA
SCHEMBL335144 0.75 ESR1 (0.45) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL335330 0.73 OPRK1 (0.50) MEN1ALDH1A1KMT2ANFKB1BLM
SCHEMBL334407 0.73 OPRK1 (0.50) MEN1ALDH1A1KMT2ANFKB1BLM
SCHEMBL19680377 0.73 ALDH1A1 (0.56) PRKCEMAPTMYLKMEN1ALDH1A1
SCHEMBL18575578 0.73 HTR1A (0.50) MAPTMEN1ALDH1A1KMT2ACYP1A2
SCHEMBL11431814 0.71 ESR1 (0.40) PRKCEMAPTMYLKMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRKCE 3313/4885MAPT 4302/4885MYLK 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.